Should I buy or sell Precigen stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Precigen in the last year. There are currently 1 sell rating and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" PGEN shares. View PGEN analyst ratings or view top-rated stocks .

What is Precigen's stock price target for 2024?

5 brokers have issued 1-year price targets for Precigen's shares. Their PGEN share price targets range from $6.00 to $14.00. On average, they expect the company's stock price to reach $9.00 in the next twelve months. This suggests a possible upside of 549.8% from the stock's current price. View analysts price targets for PGEN or view top-rated stocks among Wall Street analysts .

How have PGEN shares performed in 2024?

Precigen's stock was trading at $1.34 at the beginning of 2024. Since then, PGEN stock has increased by 3.4% and is now trading at $1.3850. View the best growth stocks for 2024 here .

When is Precigen's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 14th 2024. View our PGEN earnings forecast .

How were Precigen's earnings last quarter?

Precigen, Inc. (NASDAQ:PGEN) announced its earnings results on Tuesday, May, 14th. The biotechnology company reported ($0.10) earnings per share for the quarter, missing analysts' consensus estimates of ($0.09) by $0.01. The biotechnology company earned $1.07 million during the quarter, compared to analyst estimates of $1.54 million. Precigen had a negative trailing twelve-month return on equity of 65.36% and a negative net margin of 1,781.72%. During the same period in the previous year, the firm earned ($0.10) EPS.

What ETFs hold Precigen's stock?

ETFs with the largest weight of Precigen (NASDAQ:PGEN) stock in their portfolio include Range Cancer Therapeutics ETF (CNCR) and Loncar China Biopharma ETF (CHNA) . Virtus LifeSci Biotech Clinical Trials ETF (BBC) .

What other stocks do shareholders of Precigen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Precigen investors own include ZIOPHARM Oncology (ZIOP) , Nordic American Tankers (NAT) , Hess (HES) , Boeing (BA) , OPKO Health (OPK) , Celldex Therapeutics (CLDX) , TherapeuticsMD (TXMD) , Gilead Sciences (GILD) , NVIDIA (NVDA) and Bausch Health Companies (BHC) .

Who are Precigen's major shareholders?

Precigen's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (2.72%), Iridian Asset Management LLC CT (0.84%), Sanders Morris Harris LLC (0.28%), Fore Capital LLC (0.12%), LexAurum Advisors LLC (0.04%) and SG Americas Securities LLC (0.02%). Insiders that own company stock include Dean J Mitchell, Donald P Lehr , Harry Jr Thomasian , Helen Sabzevari , Jeffrey B Kindler, Jeffrey Thomas Perez , Randal J Kirk , Rutul R Shah, Steven Frank and Trading SA Ares. View institutional ownership trends .

How do I buy shares of Precigen?

Shares of PGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:PGEN

Precigen (PGEN) Stock Price, News & Analysis

→ This Apple-like Innovator is Revolutionizing Healthcare (From Wall Street Star) (Ad)

Free PGEN Stock Alerts

$1.38

+0.01 (+0.36%)

(As of 10:27 AM ET)

Compare

Today's Range: $1.37
▼
$1.45
50-Day Range: $1.27
▼
$1.56
52-Week Range: $0.84
▼
$1.88

Volume: 75,737 shs
Average Volume: 988,656 shs
Market Capitalization: $349.60 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $9.00

Precigen MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.60 Rating Score
Upside/Downside: 549.8% Upside
$9.00 Price Target
Short Interest: Bearish
11.81% of Float Sold Short
Dividend Strength: N/A
Sustainability: -0.77
Upright™ Environmental Score
News Sentiment: -0.20
Based on 34 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($0.35) to ($0.24) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.26 out of 5 stars

Medical Sector

142nd out of 918 stocks

Pharmaceutical Preparations Industry

58th out of 429 stocks

4.3

Analyst's Opinion

Consensus Rating
Precigen has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on 4 buy ratings, no hold ratings, and 1 sell rating.
Amount of Analyst Coverage
Precigen has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.
Read more about Precigen's stock forecast and price target.

1.0

Short Interest

Percentage of Shares Shorted
11.81% of the float of Precigen has been sold short.
Short Interest Ratio / Days to Cover
Precigen has a short interest ratio ("days to cover") of 16, which indicates bearish sentiment.
Change versus previous month
Short interest in Precigen has recently decreased by 4.70%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Precigen does not currently pay a dividend.
Dividend Growth
Precigen does not have a long track record of dividend growth.

4.7

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Precigen has received a 75.43% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Preclinical research services for physical health", "Clinical research services for cancer", and "Clinical research services for physiological diseases " products. See details.
Environmental Sustainability
The Environmental Impact score for Precigen is -0.77.

2.1

News and Social Media Coverage

News Sentiment
Precigen has a news sentiment score of -0.20. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.42 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 34 news articles for Precigen this week, compared to 2 articles on an average week.
Search Interest
11 people have searched for PGEN on MarketBeat in the last 30 days. This is an increase of 38% compared to the previous 30 days.
MarketBeat Follows
2 people have added Precigen to their MarketBeat watchlist in the last 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Precigen insiders have not sold or bought any company stock.
Percentage Held by Insiders
41.70% of the stock of Precigen is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 33.51% of the stock of Precigen is held by institutions.
Read more about Precigen's insider trading history.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Precigen are expected to grow in the coming year, from ($0.35) to ($0.24) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Precigen is -3.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Precigen is -3.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Precigen has a P/B Ratio of 2.89. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.
Read more about Precigen's valuation and earnings.

See Top Rated MarketRank™ Stocks Here

Ad Crypto 101 Media

The Overlooked Retirement Asset You Probably Don’t Own

4 out of 5 Americans believe we’re on the brink of a retirement crisis. Luckily, in these unprecedented times, we have an unprecedented solution. Once considered a “fringe” investment, the crypto market is now taking the world by storm.

Click here to access the Crypto Retirement Blueprint now.

About Precigen Stock (NASDAQ:PGEN)

Precigen, Inc. operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar. The company offers therapeutic platforms consisting of UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients; AdenoVerse immunotherapy, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and ActoBiotics for specific disease modification. It also develops programs based on the UltraCAR-T platform, including PRGN-3005 in Phase 1b clinical trial to treat advanced ovarian, fallopian tube, or primary peritoneal cancer; PRGN-3006 in Phase 1b trial for patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes; and PRGN-3007 in Phase 1/1b trial for the treatment of advanced receptor tyrosine kinase-like orphan receptor 1-positive, hematologic, and solid tumors. In addition, the company is developing programs based on the AdenoVerse immunotherapy platform comprising PRGN-2009 in Phase 2 trial for patients with HPV-associated cancer; and PRGN-2012 in Phase ½ trial to treat recurrent respiratory papillomatosis, as well as AG019, which is based on the ActoBiotics platform and in Phase 1b/2a trial, to treat type 1 diabetes mellitus. Further, it provides UltraPorator, a proprietary electroporation device; and develops research models and services for healthcare research applications. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in February 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland.

PGEN Stock Price History

30 days | 90 days | 365 days | Advanced Chart

PGEN Stock News Headlines

May 19 at 5:44 AM | americanbankingnews.com

Precigen (NASDAQ:PGEN) Earns Buy Rating from HC Wainwright

May 18 at 4:44 AM | americanbankingnews.com

FY2024 EPS Estimates for Precigen, Inc. Reduced by Analyst (NASDAQ:PGEN)

May 18 at 2:51 AM | americanbankingnews.com

Q2 2024 Earnings Forecast for Precigen, Inc. Issued By HC Wainwright (NASDAQ:PGEN)

May 18 at 1:18 AM | americanbankingnews.com

Brokerages Set Precigen, Inc. (NASDAQ:PGEN) Price Target at $9.00

May 17 at 6:39 AM | americanbankingnews.com

Precigen (NASDAQ:PGEN) Stock Rating Reaffirmed by Cantor Fitzgerald

May 17 at 5:48 AM | americanbankingnews.com

Precigen, Inc. to Post FY2028 Earnings of $0.62 Per Share, HC Wainwright Forecasts (NASDAQ:PGEN)

May 17 at 4:40 AM | americanbankingnews.com

Precigen (NASDAQ:PGEN) Rating Reiterated by Stifel Nicolaus

May 15, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Precigen Amid Promising Clinical Data and Strong Financial Outlook

May 15, 2024 | finanznachrichten.de

Precigen, Inc.: Precigen Reports First Quarter 2024 Financial Results and Business Updates

May 15, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Precigen Amid Promising Clinical Developments and Strategic FDA Alignment

May 14, 2024 | investorplace.com

PGEN Stock Earnings: Precigen Misses EPS, Misses Revenue for Q1 2024

May 14, 2024 | prnewswire.com

Precigen Reports First Quarter 2024 Financial Results and Business Updates

May 14, 2024 | markets.businessinsider.com

Here's what to expect from Precigen's earnings report

May 14, 2024 | msn.com

Stocks Mixed as US PPI Report Signals Sticky Price Pressures

May 14, 2024 | theglobeandmail.com

Stock Index Futures Tread Water Ahead of Key U.S. PPI Data and Powell Remarks

May 13, 2024 | msn.com

Precigen Q1 2024 Earnings Preview

May 12, 2024 | americanbankingnews.com

Precigen (PGEN) to Release Quarterly Earnings on Tuesday

May 8, 2024 | prnewswire.com

Precigen to Announce First Quarter 2024 Financial Results on May 14th and Host a Conference Call on June 3rd following the Late-breaking Oral Presentation for PRGN-2012 at the 2024 ASCO Annual Meeting

April 26, 2024 | finanznachrichten.de

Actym Therapeutics Inc.: Actym Therapeutics Appoints Thomas Smart as CEO

April 24, 2024 | prnewswire.com

Precigen to Present Late-breaking Abstract for Pivotal Phase 2 Study Data for PRGN-2012 AdenoVerse Immunotherapy for the Treatment of Patients with Recurrent Respiratory Papillomatosis at the 2024 ASCO Annual Meeting

April 24, 2024 | prnewswire.com

Actym Therapeutics Appoints Thomas Smart as CEO

March 28, 2024 | prnewswire.com

Precigen and Recurrent Respiratory Papillomatosis Foundation to Hold Inaugural International RRP Awareness Day on June 11th

March 26, 2024 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Precigen (PGEN), Cronos Group (CRON) and Marinus (MRNS)

March 22, 2024 | msn.com

J.P. Morgan cuts Precigen to underweight, cites burn rate

March 21, 2024 | bizjournals.com

Germantown biotech expands manufacturing capacity, headcount ahead of potential product launch

See More Headlines

Company Calendar

Last Earnings: 5/14/2024
Today: 5/20/2024
Next Earnings (Estimated): 8/14/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:PGEN
CUSIP: N/A
CIK: 1356090
Web: www.precigen.com
Phone: (301) 556-9900
Fax: N/A
Employees: 202
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $9.00
High Stock Price Target: $14.00
Low Stock Price Target: $6.00
Potential Upside/Downside: +552.2%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.60
Research Coverage: 5 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.39)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-95,900,000.00
Net Margins: -1,781.72%
Pretax Margin: -1,789.67%
Return on Equity: -65.36%
Return on Assets: -50.58%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 1.72
Quick Ratio: 2.99

Sales & Book Value

Annual Sales: $6.22 million
Price / Sales: 56.00
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.38 per share
Price / Book: 3.63

Miscellaneous

Outstanding Shares: 252,420,000
Free Float: 147,161,000
Market Cap: $348.34 million
Optionable: Optionable
Beta: 1.77

Key Executives

Mr. Randal J. Kirk J.D. (Age 71)
Executive Chairman
Comp: $100k
Dr. Helen Sabzevari MPH (Age 61)
Ph.D., President, CEO & Director
Comp: $1.29M
Mr. Harry Thomasian Jr. (Age 61)
Chief Financial Officer
Comp: $524.04k
Mr. Rutul R. Shah (Age 43)
Chief Operating Officer
Comp: $393.54k
Mr. Donald P. Lehr (Age 49)
Chief Legal Officer & Corporate Secretary
Comp: $652.4k
Mr. Jeffrey Thomas Perez (Age 52)
Senior Vice President of Intellectual Property Affairs
Comp: $570.24k
Mr. Steven Harasym
VP & Head of Investor Relations
Mr. Rob Russell
VP & Head of Human Resources
Dr. Douglas E. Brough Ph.D. (Age 69)
Senior VP & Head of Research
Dr. Bryan T. Butman Ph.D. (Age 71)
Senior VP & Head of CMC

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

PGEN Stock Analysis - Frequently Asked Questions

Should I buy or sell Precigen stock right now?: 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Precigen in the last year. There are currently 1 sell rating and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" PGEN shares.
View PGEN analyst ratings or view top-rated stocks.
What is Precigen's stock price target for 2024?: 5 brokers have issued 1-year price targets for Precigen's shares. Their PGEN share price targets range from $6.00 to $14.00. On average, they expect the company's stock price to reach $9.00 in the next twelve months. This suggests a possible upside of 549.8% from the stock's current price.
View analysts price targets for PGEN or view top-rated stocks among Wall Street analysts.
How have PGEN shares performed in 2024?: Precigen's stock was trading at $1.34 at the beginning of 2024. Since then, PGEN stock has increased by 3.4% and is now trading at $1.3850.
View the best growth stocks for 2024 here.
When is Precigen's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 14th 2024.
View our PGEN earnings forecast.
How were Precigen's earnings last quarter?: Precigen, Inc. (NASDAQ:PGEN) announced its earnings results on Tuesday, May, 14th. The biotechnology company reported ($0.10) earnings per share for the quarter, missing analysts' consensus estimates of ($0.09) by $0.01. The biotechnology company earned $1.07 million during the quarter, compared to analyst estimates of $1.54 million. Precigen had a negative trailing twelve-month return on equity of 65.36% and a negative net margin of 1,781.72%. During the same period in the previous year, the firm earned ($0.10) EPS.

What ETFs hold Precigen's stock?: ETFs with the largest weight of Precigen (NASDAQ:PGEN) stock in their portfolio include Range Cancer Therapeutics ETF (CNCR) and Loncar China Biopharma ETF (CHNA).Virtus LifeSci Biotech Clinical Trials ETF (BBC).
What other stocks do shareholders of Precigen own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Precigen investors own include ZIOPHARM Oncology (ZIOP), Nordic American Tankers (NAT), Hess (HES), Boeing (BA), OPKO Health (OPK), Celldex Therapeutics (CLDX), TherapeuticsMD (TXMD), Gilead Sciences (GILD), NVIDIA (NVDA) and Bausch Health Companies (BHC).
Who are Precigen's major shareholders?: Precigen's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (2.72%), Iridian Asset Management LLC CT (0.84%), Sanders Morris Harris LLC (0.28%), Fore Capital LLC (0.12%), LexAurum Advisors LLC (0.04%) and SG Americas Securities LLC (0.02%). Insiders that own company stock include Dean J Mitchell, Donald P Lehr, Harry Jr Thomasian, Helen Sabzevari, Jeffrey B Kindler, Jeffrey Thomas Perez, Randal J Kirk, Rutul R Shah, Steven Frank and Trading SA Ares.
View institutional ownership trends.
How do I buy shares of Precigen?: Shares of PGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:PGEN) was last updated on 5/20/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Get Started with MarketBeat

	Read Your Daily Newsletter
	Check Out My MarketBeat
	Watch Our Tutorial Videos
	Add a Stock to Your Watchlist
	Set Up an Instant Alert
	View a Company's Profile Page
	View Our Financial Calendars
	View Today's Analyst Ratings

Precigen (PGEN) Stock Price, News & Analysis

Precigen MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Consensus Rating

Amount of Analyst Coverage

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Dividend Yield

Dividend Growth

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows